🇺🇸 Copegus (ribavirin) in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Chills — 2 reports (18.18%)
  2. Acute Prerenal Failure — 1 report (9.09%)
  3. Altered State Of Consciousness — 1 report (9.09%)
  4. Asthenia — 1 report (9.09%)
  5. Bedridden — 1 report (9.09%)
  6. Decreased Appetite — 1 report (9.09%)
  7. Dehydration — 1 report (9.09%)
  8. Fluid Retention — 1 report (9.09%)
  9. Gastrointestinal Disorder Congenital — 1 report (9.09%)
  10. Hyperhidrosis — 1 report (9.09%)

Source database →

Other Virology/Infectious Disease approved in United States

Frequently asked questions

Is Copegus (ribavirin) approved in United States?

Copegus (ribavirin) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Copegus (ribavirin) in United States?

Hoffmann-La Roche is the originator. The local marketing authorisation holder may differ — check the official source linked above.